CD274 and non-small cell lung carcinoma: Taken together, our meta-analysis complements prior work by providing a more comprehensive overview across different PD-1/PD-L1 inhibitors and NSCLC subtypes, while also highlighting that efficacy and safety profiles may vary depending on histology and study design.